Barclays
KYMR icon

Barclays’s Kymera Therapeutics KYMR Stock Holding History

Barclays’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,400
Closed -$1.49M – 5386
2024
Q3 		$1.49M Buy
+31,400
New +$1.39M ﹤0.01% 3091

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Barclays's KYMR Position: Q2 2026 in Review

Barclays increased its Kymera Therapeutics (KYMR) stake by 78% in Q2 2026, buying an estimated $955K and bringing the position to 25,364 shares worth $2.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2144.

Barclays first reported a position in KYMR in Q1 2022 and has held it in 18 quarters since. The position peaked at $12.9M in Q1 2024. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Barclays held 25,364 shares of Kymera Therapeutics worth $2.91M as of Q2 2026.
  • Barclays bought 11,117 Kymera Therapeutics shares in Q2 2026, an estimated $955K.
  • Kymera Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2144 holding.
  • Barclays first reported a position in Kymera Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Kymera Therapeutics position peaked at $12.9M in Q1 2024.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.